KALA BIO, Inc. (KALA)

Market Cap	27.29M
Revenue (ttm)	n/a
Net Income (ttm)	-38.96M
Shares Out	4.61M
EPS (ttm)	-11.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,938
Open	5.78
Previous Close	5.90
Day's Range	5.75 - 6.04
52-Week Range	4.21 - 9.25
Beta	-2.14
Analysts	Strong Buy
Price Target	15.00 (+153.38%)
Earnings Date	Nov 12, 2024

About KALA

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, I...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: KALA
• Website: https://www.kalarx.com

Analyst Forecast

According to 2 analysts, the average rating for KALA stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 153.38% from the latest price.

Price Target

$15.0

(153.38% upside)

Analyst Consensus: Strong Buy